8-K: Tevogen Bio Receives Nasdaq Delisting Warning

Tevogen Bio Holdings Inc. received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement for continued listing.

Summary

• Tevogen Bio Holdings Inc. (TVGN) received a letter from The Nasdaq Stock Market LLC on September 23, 2025, notifying the company of non-compliance with Nasdaq Listing Rule 5450(a)(1).
• The non-compliance is due to the company's common stock closing bid price being below the minimum $1.00 per share requirement for 30 consecutive business days.
• This notification does not have an immediate effect on the company's listing or trading on the Nasdaq Global Market.
• Tevogen Bio has a period of 180 calendar days, until March 23, 2026, to regain compliance with the Bid Price Requirement.
• To regain compliance, the common stock's bid price must close at $1.00 or more for a minimum of 10 consecutive business days (and generally not more than 20 consecutive business days).
• If compliance is not regained by March 23, 2026, the company may be eligible for an additional 180-day compliance period if it transfers to the Nasdaq Capital Market and meets other listing standards, excluding the bid price requirement.
• The company intends to actively monitor its common stock's closing bid price and evaluate available options to regain compliance, though there is no assurance of success.

Sentiment

Score: 3

Explanation: Receipt of a Nasdaq delisting notice due to failure to meet the minimum bid price requirement is a significant negative event, indicating potential challenges for the company's stock performance and market perception. While there is a compliance period, the underlying issue of low stock price is concerning.

Negatives

• Failure to meet Nasdaq's minimum $1.00 bid price requirement for continued listing.
• Receipt of a formal delisting notice from Nasdaq.

Risks

• Potential delisting of common stock and warrants from The Nasdaq Stock Market LLC if compliance is not regained.
• Inability to regain compliance with the Bid Price Requirement within the specified timeframe.
• Failure to qualify for or meet the requirements of a second 180-day compliance period.
• Impact on stock liquidity and investor confidence due to non-compliance and potential delisting.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and evaluate available options to regain compliance. However, there is no assurance that the company will take any specific action or be able to regain compliance or maintain compliance with Nasdaq listing rules.

Management Comments

• Management intends to actively monitor the closing bid price of the Common Stock in addition to its ongoing monitoring of the market integrity of the Common Stock.
• Management may evaluate and consider available options to regain compliance with the Bid Price Requirement.

Industry Context

Many small-cap biotechnology companies, particularly those in early development stages without significant commercial revenue, face challenges with stock price volatility and meeting exchange listing requirements. Delisting from a major exchange like Nasdaq can significantly impact a company's ability to raise capital, its stock's liquidity, and its overall market perception, which is a common concern in the high-risk, high-reward biotech sector.

Comparison to Industry Standards

• Many small-cap biotechnology companies face similar challenges regarding stock price volatility and meeting listing requirements, especially those in early development stages without significant commercial revenue.
• No specific comparable companies, projects, or results were mentioned in the filing for direct comparison.

Stakeholder Impact

• Shareholders face potential risks of reduced liquidity and investor confidence if the company's stock is delisted from Nasdaq.
• Potential impact on the company's ability to attract future investment and maintain its public market profile.

Next Steps

• Actively monitor the closing bid price of the common stock.
• Evaluate and consider available options to regain compliance with the Bid Price Requirement.
• Aim to achieve a closing bid price of $1.00 or more for a minimum of 10 consecutive business days by March 23, 2026.
• If necessary, explore eligibility for an additional 180-calendar day compliance period by transferring to the Nasdaq Capital Market and meeting other listing standards.

Key Dates

Recommendation

The company received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement. While there is a compliance period and the company intends to monitor and evaluate options, the uncertainty surrounding its ability to regain compliance and the potential impact of delisting on liquidity and investor confidence warrant a cautious 'hold' recommendation. Investors should monitor the company's progress in addressing this issue and assess any fundamental business developments.

Keywords

Tevogen Bio, TVGN, Nasdaq, Delisting Notice, Minimum Bid Price, Compliance, SEC 8-K, Biotechnology